

23 *Co-correspondent authors

24 *Lead contact:

25 Haipeng Xiao, MD, PhD

26 Professor of Medicine in Endocrinology

27 President of the First Affiliated Hospital of Sun Yat-sen University

28 58 ZhongShan Second Road, Guangzhou, 510080, P. R. China.

29 Tel: +86-136-0976-3571

30 E-mail: xiaohp@mail.sysu.edu.cn

31

32 **Abstract:**

33 SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical
34 trials, especially in reducing severe illness and casualty. However, the waning
35 of humoral immunity over time has raised concern over the durability of
36 immune memory following vaccination. Thus, we conducted a non-randomized
37 trial among the healthcare professionals (HCWs) to investigate the long-term
38 sustainability of SARS-CoV-2-specific B cells and T cells stimulated by
39 inactivated vaccines and the potential need for a third booster dose. Although
40 neutralizing antibodies elicited by the standard two-dose vaccination schedule
41 dropped from a peak of 29.3 AU/ml to 8.8 AU/ml 5 months after the second
42 vaccination, spike-specific memory B and T cells were still detectable, forming
43 the basis for a quick recall response. As expected, the faded humoral immune
44 response was vigorously elevated to 63.6 AU/ml by 7.2 folds 1 week after the
45 third dose along with abundant spike-specific circulating follicular helper T cells
46 in parallel. Meanwhile, spike-specific CD4⁺ and CD8⁺ T cells were also
47 robustly elevated by 5.9 and 2.7 folds respectively. Robust expansion of
48 memory pools by the third dose potentiated greater durability of protective
49 immune responses. Another key finding in this trial was that HCWs with low
50 serological response to 2 doses were not truly “non-responders” but fully
51 equipped with immune memory that could be quickly recalled by a third dose
52 even 5 months after the second vaccination. Collectively, these data provide
53 insights into the generation of long-term immunological memory by the

54 inactivated vaccine, which could be rapidly recalled and further boosted by a

55 third dose.

56

57 **Key words:** SARS-CoV-2, inactivated vaccine, immunological memory,

58 SARS-CoV-2-specific memory B cells, SARS-CoV-2-specific memory T cells,

59 booster dose

60

61 **Introduction**

62 The coronavirus disease 2019 (COVID-19), caused by the severe acute
63 respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread
64 across the globe currently^{1, 2}. The pandemic has brought profound casualties
65 of human lives and socioeconomic issues. The establishment of herd immunity
66 by vaccination represents the most cost-effective strategy to prevent
67 COVID-19. The rapid spreading of COVID-19 has urged the governments to
68 authorize the emergent use of vaccines against SARS-CoV-2³⁻⁵.

69

70 The presence of neutralizing antibodies (NAbs) against SARS-CoV-2 is an
71 indicator of protective immunity after vaccination or infection^{6, 7}. NAbs capable
72 of blocking the interaction between the spike protein and its receptor
73 angiotensin converting enzyme 2 (ACE2) are particularly important for
74 protection from COVID-19⁸. Therefore, inducing potent NAbs and long-lasting
75 memory B cells are the primary goal of SARS-CoV-2 vaccines. Two doses of
76 mRNA or inactivated vaccines are capable of inducing potent neutralizing
77 antibody responses^{9,3, 10}. Our previous study further demonstrated that
78 inactivated vaccines elicited SARS-CoV-2 specific memory B cells¹¹, which are
79 important for a rapid and robust recall of protective responses against viral
80 infection. However, little is known how long can these immune responses
81 sustain. A rapid decline of neutralizing antibodies has been observed among
82 infected healthcare workers (HCWs)¹². Neutralizing antibodies also waned

83 overtime after the second dose of BNT162b2 or ChAdOx1¹³, indicating
84 weakened protection for SARS-CoV-2 infection. In addition, the rapid
85 emergence of novel SARS-CoV-2 variants of concern (VOCs) dampens the
86 efficacy of SARS-CoV-2 vaccines, since vaccine-induced antibodies were less
87 effective in neutralizing some emerging VOCs¹⁴. Moreover, cross-reactive
88 antibodies against VOCs decayed even faster than antibodies against
89 wild-type strain¹⁵.

90

91 Besides humoral immune responses, T cells also play a pivotal role in
92 coordinating the adaptive immune responses and as effectors against viral
93 infection. In some cases, patients with inherited or treatment-induced B cell
94 deficiency were able to recover from COVID-19^{16, 17}, suggesting a potential
95 role of cellular responses in fighting against SARS-CoV-2 infection. Induction
96 of CD8⁺ T cell responses was documented in both SARS-CoV-2 infection and
97 vaccination^{18, 19}. On the other hand, rapid induction of CD4⁺ T cells is
98 associated with coordinated humoral and cellular response to a SARS-CoV-2
99 mRNA vaccine²⁰. SARS-CoV-2 specific circulating T follicular helper cells
100 (cTFH) cells, whose counterparts in lymph nodes reinforce B cells and humoral
101 responses²¹, correlated with neutralizing antibody levels in convalescent
102 COVID-19 patients^{22, 23}.

103

104 Nevertheless, T cell responses induced by inactivated vaccines are much less

105 well characterized than humoral immunity. One previous study revealed that
106 the inactivated vaccine could elicit T cells response after 2 doses of
107 vaccination²⁴, but the phenotype and sustainability of antigen-specific CD4⁺
108 and CD8⁺ T cells remained unclear yet.

109

110 In this study, we sought to investigate the sustainability of immune memory
111 stimulated by the inactivated vaccine and profile humoral and cellular
112 responses to a third dose among HCWs. Although NAbs declined substantially,
113 SARS-CoV-2-specific memory B, CD4⁺, and CD8⁺ T cells persisted in the
114 peripheral blood 5 months after the second vaccination, even in participants
115 who were seronegative after receiving 2 doses of the inactivated vaccines. The
116 third vaccination robustly recalled both humoral and cellular immune
117 responses in all participants.

118

119 **Materials and methods**

120 **Human subjects**

121 In this study, we conducted a non-randomized trial and recruited participants
122 from a prospective cohort at the First Affiliated Hospital of Sun Yat-sen
123 University (FAH-SYSU) in Guangzhou, China. As we described previously¹¹,
124 63 HCWs received the inactivated SARS-CoV-2 vaccine BBIBP-CorV
125 (BBIBP-CorV, Sinopharm, Beijing) in the morning (9 am – 11 am) or afternoon
126 (3 pm – 5 pm) on day (d) 0 and d28, respectively. Fifty of the 63 HCWs were

127 volunteered to receive a third booster shot of the inactivated vaccine 6 months
128 after the prime vaccination (d180). They were assigned to the morning or
129 afternoon group as to their previous vaccinating time accordingly.
130 Demographic characteristics of the HCWs were summarized in Supplementary
131 Table 1. Blood samples were collected on d180 before the booster dose and
132 d187, d194 and d208 after the booster dose. Convalescent patients who had
133 recovered from SARS-CoV-2 infection were recruited as the positive control
134 (Supplementary Table 2). All studies were approved by the Institutional Review
135 Board of FAH-SYSU and written consent was obtained from all participants.
136 The prospective cohort and the trial were registered to Chinese Clinical Trial
137 Registry (ChiCTR2100042222 and ChiCTR2100048665).

138

139 **Cell isolation**

140 Blood samples were collected into the heparinized tubes and processed right
141 after sample collection. Peripheral blood mononuclear cells (PBMCs) were
142 isolated using density-gradient centrifugation. Briefly, blood samples were
143 diluted with PBS at 1:1 ratio and loaded on top of Lymphoprep™ (StemCell) in
144 the Falcon tubes. The falcon tubes were then centrifuged at 1500 rpm for 30
145 mins. The medium layer was collected and washed with PBS twice. PBMCs
146 were cryopreserved in Bambanker (StemCell) immediately.

147

148 **SARS-CoV-2 neutralizing antibodies measurement**

149 A one-step competitive Chemiluminescent immunoassay was used to detect
150 the concentration of NAbS against SARS-CoV-2 in sera by iFlash 2019-nCoV
151 NAb kit (YHLO Biotech Co, Ltd) as previously reported²⁵. In this assay,
152 receptor binding domain (RBD) of the SARS-CoV-2 was coated on magnetic
153 beads. Acridinium ester-labeled ACE2 was designed to compete with
154 SARS-CoV-2 NAbS in sera for the RBD. NAb titers were calculated by an
155 iFlash3000 Chemiluminescence Immunoassay Analyzer (YHLO Biotech Co,
156 Ltd). Neutralizing activity is determined in arbitrary units (AU) and the cut-off is
157 10 AU/ml.

158

159 **Ex vivo ELISpot assay**

160 IFN γ ELISpot assays were performed as described previously²⁶. Briefly, 100 μ l
161 of the coating antibody (15 μ g/ml, MabTech, #3420-3-250) was added to the
162 well of ELISpot plate (MabTech) and incubated overnight at 4°C. The peptide
163 pool of SARS-CoV-2 spike protein (MabTech, #3630-1) was added to 300,000
164 PBMCs per test at a final concentration of 2 μ g/ml for 24 h. Unstimulated cells
165 were used as negative control while anti-CD3/CD28 dynabeads (Thermo
166 Fisher) stimulated cells were set as the positive control. Plates were incubated
167 with IFN γ detection antibody (1 μ g/ml, MabTech, #3420-6-250), followed by
168 Avidin-HRP (1 μ g/ml, Vector, #A-2004-5) and visualized using the ACE
169 substrate. Antigen-specific T cell responses were quantified by subtracting the
170 number of spots in unstimulated cells from the peptide stimulated cells.

171

172 SARS-CoV-2-specific B cell ELISpot was performed as previously described²⁷.

173 Briefly, ELISpot plates were coated with 10 ug/ml recombinant RBD protein

174 (Sino Biological, #40592-VNAH-100) and 8 ug/ml spike protein (Sino

175 Biological, #40589-V08B1) overnight at 4°C. To optimize the human IgG B cell

176 ELISpot assay, PBMCs were cultured with a mixture of R848 (1 µg/ml, Tocris,

177 #4536/10) and IL-2 (20 ng/ml, PeproTech, #200-02-10) for 3 days to secrete a

178 detectable amount of antibody^{28, 29}. After pre-stimulation, cells were washed

179 extensively to remove secreted antibodies. 500,000 PBMCs were added to the

180 coated plates and incubated for 18 h at 37°C with 5% CO₂. The following day,

181 cells were removed and plates were incubated with Biotin-anti-Human IgG

182 (1µg/ml, Jackson ImmunoResearch, #709-065-098). Plates were then

183 incubated with Avidin-HRP followed by visualization with ACE substrate.

184 ELISpot plates were analyzed using an ELISpot counter (Cellular

185 Technologies Ltd). Results were expressed as spot-forming units (s.f.u.) per

186 10⁶ PBMCs. Responses were considered positive if the results were at least

187 three times the mean of the negative control wells and >25 s.f.u. per 10⁶

188 PBMCs. Data were excluded when negative control wells had >30 s.f.u. per

189 10⁶ PBMCs or positive control wells (anti-CD3/CD28 dynabeads) had no spot.

190

191 **Activation-induced markers (AIM) T cell assay.**

192 PBMCs were cultured in RPMI 1640 supplemented with 10% FBS and 1%

193 penicillin and streptomycin (Thermo Fisher) at 37 °C overnight. The cells were
194 then cultured with or without the peptide pool of SARS-CoV-2 spike protein (2
195 µg/ml) for 12 h. An equal concentration of DMSO in PBS was used as the
196 negative control. Antigen-specific T cells were measured as a percentage of
197 AIM⁺ (OX40⁺CD137⁺) for CD4⁺ T or (CD69⁺CD137⁺) for CD8⁺ T cells after
198 stimulation of PBMCs with the peptide pool of spike protein²⁶. After the
199 stimulation, cells were first stained with Zombie Red for dead cell exclusion.
200 Cells were then stained with anti-CD3-Pacific blue, anti-CD4-BV510,
201 anti-CD8-Percp, anti-CD69-Super Bright 436, anti-CD134 (OX40)-BV605 and
202 anti-CD137-(4-1BB)-PE antibodies for antigen-specific T cell analysis. As for
203 phenotype analysis of SARS-CoV-2-specific T cells, cells were further labeled
204 with anti-CCR7-APC/cy7, anti-CD45RA-BV650, anti-CXCR5-BV711 and
205 anti-PD-1-PE/cy7 antibodies. All FACS antibodies were from Biolegend.
206 Stimulation with anti-CD3/CD28 dynabeads was included as positive controls.
207 Any sample with a low response to anti-CD3/CD28 stimulation was excluded
208 as quality control for the samples. Data were acquired by flow cytometry.

209

210 **Detection of SARS-CoV-2-specific memory B cells**

211 SARS-CoV-2-specific memory B cells were detected as we described
212 previously¹¹. First, biotinylated antigens were multimerized with
213 fluorescence-labeled streptavidin individually. Recombinant spike protein
214 (R&D, #BT10549-050) was mixed with BV510-streptavidin (BioLegend) at 10:1

215 ratio and BV785-streptavidin (BioLegend) at 18:1 ratio at 4°C for 1h.
216 Recombinant RBD protein (R&D, #BT10500-050) was mixed with
217 BV421-streptavidin (BioLegend) at 20:1 ratio at 4°C for 1h. The antigen probes
218 prepared above were then mixed in 50mM free d-biotin (Macklin) in PBS to
219 ensure minimal cross-reactivity. PBMCs were thawed and let to rest at 37°C
220 with 5% CO₂ for 2h and stained with Zombie Red (BioLegend) in PBS at room
221 temperature for 20 min. Cells were then stained with 50 µl of antigen probe
222 cocktail containing 100 ng of spike and 50 ng of RBD at 4°C for 30 min. Cells
223 were washed with PBS and then stained with the following antibody cocktail:
224 anti-CD3-Pacific Blue™, anti-CD19-PE-CY7, anti-CD27-AF700, anti-IgD-FITC,
225 anti-CD38-BV650, anti-IgM-BV605, anti-IgG-AF647, anti-IgA-PE all from
226 BioLegend at 1:100 dilution. Samples were acquired by flow cytometry.

227

228 **Detection of SARS-CoV-2-specific IFN γ -producing T cells**

229 The detection of spike-reactive T cells was performed as described with
230 modification³⁰. Briefly, overnight-rested PBMCs were cultured with or without
231 the peptide pool of SARS-CoV-2 spike protein (4 µg/ml) in the presence of 3
232 µg/ml of anti-CD28 monoclonal antibodies for 24 h. Cells were then incubated
233 with Brefeldin A for additional 5 h. Cells were stained with anti-CD3-Pacific
234 blue, anti-CD4-BV510, anti-CD8-Percp antibodies for surface markers. Cells
235 were then washed, fixed with Cytofix/Cytoperm and stained with
236 anti-IFN γ -PE-Cy7 (BioLegend). Dead cells were excluded by Zombie Red

237 staining. Samples were analyzed by flow cytometry. Samples without peptide
238 stimulation were used as the negative control.

239

240 **Flow cytometry**

241 All flow cytometry samples were analyzed using cryopreserved cells which
242 were thawed and suspended in RPMI 1640 media supplemented with 2% FBS.
243 All samples were analyzed by flow cytometry with Cytex™ AURORA. FlowJo
244 (Tree Star, USA) software was used for FACS data analysis. Details of
245 antibodies used in this study are listed in Supplementary Table 3.

246

247 **ELISA-based antibody-antigen distribution analysis**

248 All SARS-CoV-2 proteins were purchased from Sino Biological (Beijing,
249 China). 200ng/well of SARS-CoV-2 spike (40589-V08B1), spike S1 subunit
250 (40591-V08H), spike NTD (40591-V49H), spike S2 subunit (40590-V08B),
251 RBD (40592-V08H), RBD T478K (40592-V08H91), nucleocapsid
252 (40588-V08B) and envelope (40609-V10E3) were coated on the 96-well
253 ELISA plate overnight at 4 °C, respectively. Plates were washed by PBS
254 supplemented with 0.05% Tween-20 (PBST) three times, followed by blocking
255 with 5% BSA in PBST for 1 h at room temperature. Sera were diluted 20-fold
256 for the first well and 4-fold serial diluted for subsequent wells in 5% BSA in
257 PBST, and incubated at 4°C overnight. Plates were washed 3 times by PBST,
258 and added with HRP-conjugated goat anti-human IgG antibody (2040-05,

259 SouthernBiotech, 1:3000) for 30 min at room temperature. Plates were
260 washed five times with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) substrate
261 (P0209, Beyotime) was added for 15 min, and stopped by the stopping buffer
262 (C1058, Solarbio). OD450 was measured by Varioskan Lux Microplate Reader
263 (Thermo Fisher).

264

265 **Pseudovirus neutralizing assay**

266 For the generation of SARS-CoV-2-Spike (Wuhan-Hu-1) pseudovirus ³¹,
267 pcDNA3.1-2019-nCoV-Spike and pNL4-3 R⁻E⁻ (gifts from Dr. Lu Lu, Fudan
268 University) were co-transfected to HEK293T with Lipo8000 (C0533, Beyotime)
269 according to the manufacturer's instruction. For the generation of the
270 B.1.617.2 Delta-variant spike pseudovirus, pCMV3-SARS-CoV-2-Spike
271 (VG40804-UT, Sino Biological), pSPAX2 and pLenti-CMV-Luc-puro were
272 co-transfected to HEK293T. The virus was harvested 72 hours
273 post-transfection and stored at -80°C until use. 2x10⁴ hACE2-293T/well were
274 seeded on the black flat-bottom 96-well plate (655090, Greiner Bio-one) for 16
275 hours in advance. Sera were diluted 10-fold for the first well and 4-fold serial
276 diluted for subsequent wells in DMEM, then co-incubated with pseudovirus at
277 37°C for 1 hour. Then the co-incubated samples, together with samples
278 without sera or pseudovirus as controls, were subjected with 10µg/ml
279 polybrene (C0351, Beyotime) to the hACE2-293T for 6-hour absorption,
280 following by replacement of the culture medium for the next 42 hours

281 incubation at 37°C, 5% CO₂. Infected cells were processed to the luciferase
282 assay using the Luciferase Assay System (E4550, Promega). The
283 illuminance was measured by Varioskan Lux Microplate Reader (Thermo
284 Fisher). The 50% pseudovirus neutralization titer (pNT50) were determined by
285 four-parameter nonlinear regression curve (GraphPad Prism).

286

287 **Statistical analysis**

288 Statistical analysis was performed using Prism 5.0. Comparisons were
289 assessed using Wilcoxon rank sum test, Student's t-test, paired Student's t-test
290 or One-way ANOVA followed by Bonferroni's multiple comparison post-test as
291 appropriate. P values < 0.05 were considered as statistically significant.

292

293 **Results**

294 **Neutralizing antibody response is enhanced by a third dose of** 295 **inactivated SARS-CoV-2 vaccine BBIBP-CorV.**

296 We have previously conducted a non-randomized trial and recruited HCWs
297 from a prospective cohort, demonstrating the impact of the circadian rhythm on
298 the immune response induced by a primary 2-dose series of the inactivated
299 SARS-CoV-2 vaccine (BBIBP-CorV, Sinopharm, Beijing)¹¹. Fifty HCWs from
300 this cohort were volunteered to participate in the current non-randomized trial
301 to investigate the duration of the primary vaccination regimen and potential
302 benefits of a third dose, given 5 months after the second dose (Fig. 1A). No

303 severe side effects related to vaccination were recorded during the trial
304 (Supplementary Table 1).

305

306 Blood samples were collected from multiple time points before and after each
307 dose and NAbs targeting RBD were measured by Chemiluminescent
308 immunoassay²⁵. The mean serum concentration of NAbs dropped by 70%
309 from d56 (1 month post the second dose) to d180, 5 months after the second
310 dose (Fig. 1B). Intriguingly, NAbs maintained a significantly higher level in the
311 morning vaccination group than that in the afternoon group on d180 (Fig. 1D).

312

313 Although serum NAbs in 72% of participants (36/50) dropped below the
314 threshold (10 AU/ml) on d180, serological responses could be rapidly recalled
315 to an unprecedented level within 1 week after the third dose. The mean
316 concentration of NAbs was increased by 7.2 folds from 8.8 AU/ml on d180 to
317 63.6 AU/ml on d187, peaking at 92.3 AU/ml 2 weeks after the booster (Fig. 1C).

318 As the primary vaccination series¹¹, the circadian rhythm also governed the
319 outcome of the third dose, albeit only at the early stage. Significantly higher
320 levels of NAbs were observed in the morning group after the third dose on
321 d187 (Fig. 1D). However, the difference between the morning and the
322 afternoon groups gradually diminished over time (Fig. 1D). Moreover, we did
323 not observe any difference in NAbs levels between females and males (Fig.
324 1E).

325

326 Pseudovirus neutralizing assays were next applied to confirm the elevation of
327 serum NAbs against wild type (WT) SARS-CoV-2 and VOCs by the third dose.
328 Consistent with the results of Chemiluminescent immunoassay, the 50%
329 pseudovirus neutralization titer (pNT50) against WT was greatly boosted (Fig.
330 1F). Encouragingly, the third dose not only elevated the NAbs against WT, but
331 also strengthen a cross-protective immune response. The mean serum pNT50
332 against B.1.167.2 Delta variant was increased by 10-fold from day180 to
333 day194 (Fig. 1G). In pseudovirus assay, a significantly higher level of NAbs
334 against both WT and B.1.167.2 could still be observed in morning vaccination
335 participants (Fig. 1H and I).

336

337 One potential advantage of inactivated vaccines over other vaccine types is
338 that they comprise all viral structural proteins which may induce a broader
339 spectrum of immunity in addition to NAbs against RBD. To profile the antibody
340 spectrum induced by BBIBP-CorV, serum IgG against major SARS-CoV-2
341 structural proteins and their subdomains, including S1, S2, RBD, NTD of spike
342 protein, nucleocapsid, and small envelope protein, were measured by indirect
343 ELISA before and after the third dose. As expected, BBIBP-CorV successfully
344 elicited antibodies against all structural proteins and subdomains tested
345 (Supplementary Fig. 1). Notably, we found all vaccinees were equipped with a
346 high titer of anti-envelope IgG which has not been reported in a vaccine study

347 elsewhere and was hardly induced even during natural SARS-CoV-2
348 infection³². Interestingly, the third dose did not elevate antibody responses
349 against all tested structural proteins or subdomains evenly, but profoundly
350 augment the immune response against the S1 domain of spike protein which
351 comprises NTD and RBD subdomains (Supplementary Fig. 1).

352

353 **SARS-CoV-2 specific memory B cell response is robustly induced by a**
354 **third dose of inactivated vaccine**

355 The rapid and robust recall of humoral immune responses by the third
356 vaccination indicated that the primary 2-dose vaccination regimen has
357 established a sustained immune memory. We explored the presence of
358 antigen-specific memory B cells before and after the third dose by flow
359 cytometry.

360

361 Total B cell populations were first characterized by flow cytometry
362 (Supplementary Fig. 2). Only mild changes in IgD⁺, IgM⁺, IgA⁺ or IgD⁻CD27⁻ B
363 cells were found before and after the booster, whereas the percentage of total
364 and naïve B cells were not affected (Supplementary Fig. 3), consistent with a
365 good safety profile of the third dose (Supplementary Table. 1).

366

367 Next, antigen-specific B cell populations were investigated. Spike- and
368 RBD-specific memory B cells could be detected at 4 weeks (d56) and 5

369 months (d180) after the second dose, revealing that memory B cells persisted
370 despite a decreasing trend over a 5-months time frame between second and
371 third immunization (Fig. 2A and C). The third dose increased the percentages
372 of spike- and RBD-specific memory B cells by 1.7 and 2.0 folds respectively
373 from d180 to d187, resulting in a significantly larger memory pool on d187 than
374 that on d56 (Fig. 2B and D). The majority of these antigen-specific memory B
375 cells could be classified into IgG⁺ or IgM⁺ B cells, while a minor population of
376 them was IgA⁺ B cells (Fig. 2E and F).

377

378 The capability of these Spike- or RBD-specific memory B cells in secreting
379 antibodies upon the antigen stimulation was further confirmed by B cell
380 ELISpot. The third dose boosted spike- or RBD-responsive, IgG-secreting B
381 cells from 8 u.f.c/10⁶ PBMCs to 17 u.f.c/10⁶ PBMCs or 4 u.f.c/10⁶ PBMCs to
382 10.7 u.f.c/10⁶ PBMCs respectively (Fig. 2G-I). These results demonstrated that
383 the primary 2-dose vaccination regimen had equipped vaccinees with
384 long-lasting memory B cells which could be immediately recalled and further
385 expanded by a third dose of the inactivated vaccine.

386

387 **The cellular immune response is boosted by a third dose of inactivated** 388 **SARS-CoV-2 vaccine**

389 Besides humoral immune responses, the cellular arm of immunity confers
390 another layer of protection, which may particularly crucial when B cell epitopes

391 mutate rapidly and continuously. Therefore, antigen-specific T cells induced by
392 the primary vaccination regimen and the third dose booster were next
393 investigated. Blood samples collected on d180 and d187 were stimulated by
394 the spike peptide pool and IFN γ -secreting cells were quantified by ELISpot.
395 Surprisingly, antigen-responsive IFN γ -secreting T cells were readily detected
396 in all vaccinees even 5 months after the second dose, though a lower amount
397 was found in some participants (Fig. 3A and B). As IgG-secreting B cells,
398 IFN γ -secreting T cell responses were also enhanced by 2.3 folds after the third
399 dose (Fig. 3A and B).

400

401 Next, SARS-CoV-2-specific CD8⁺ were identified by AIM T cell assay, based
402 on the previous observation that antigen-specific CD8⁺ T cells could be
403 identified by CD69⁺4-1BB⁺ after the peptide pool stimulation²⁶. In line with
404 ELISpot, CD8⁺CD69⁺4-1BB⁺ T cells were seen on d180, and further elevated
405 by 2.7 folds following a booster shot (Fig. 3C and D). Subsequent analysis on
406 phenotypic markers revealed that the majority of the SARS-CoV-2-specific
407 CD8⁺ T cells were CD45RA⁺CCR7⁻ terminally differentiated effector memory
408 cells (T_{EMRA}), whereas CD45RA⁻CCR7⁻ effector memory T cells (T_{EM})
409 accounted for only one-fourth of the total antigen-specific CD8⁺ T cells (Fig.
410 3E), similar to that from recovered COVID-19 patients²⁶. The subsets of total
411 CD8⁺ T cells were not affected (Supplementary Fig. 4 and Fig. 5). The
412 presence of antigen-specific CD8⁺ T cells was further confirmed by

413 conventional intracellular cytokine staining (ICS) assay, in which PBMCs were
414 stimulated with spike peptide pool and IFN γ expression in CD8⁺ T cells was
415 measured by flow cytometry. CD8⁺ IFN γ ⁺ T cells were detected on d56, and
416 decreased over time till the third vaccination, which elevated IFN γ -expressing
417 CD8⁺ T cells to a greater extent when compared to that on d56 (Fig. 3H and I).

418

419 SARS-CoV-2-specific CD4⁺ T cells were identified by activation markers OX40
420 and 4-1BB after the peptide stimulation²⁶. CD4⁺OX40⁺4-1BB⁺ T cells were
421 detected at a low level on d180. The third dose induced the expansion of these
422 CD4⁺ T cells by 5.9 folds within 1 week (Fig. 4A and B). Phenotypic analysis
423 showed that the majority of the SARS-CoV-2-specific CD4⁺ T cells were
424 CD45RA⁻CCR7⁺ T_{CM} and CD45RA⁻CCR7⁻ T_{EM}, different from that of
425 SARS-CoV-2-specific CD8⁺ T cells (Fig. 4C). Among SARS-CoV-2-specific
426 CD4⁺ T cells, 57.7% of the cells were CXCR5⁺ cTFH cells (Fig. 4D-G). Among
427 total CD4⁺ T cells, we observed the slightly decreased T_N cells, with increased
428 T_{EM} and T_{CM} cells in the peripheral blood (Supplementary Fig. 4 and Fig. 5).
429 Again, SARS-CoV-2-specific CD4⁺ T cells were confirmed by ICS assay.
430 CD4⁺ IFN γ ⁺ T cells showed a similar trend as that of CD8⁺ IFN γ ⁺ T cells. As
431 expected, the drop of antigen-specific CD4⁺ T cells was reversed by the third
432 dose (Fig. 4H and I).

433

434 Besides CD4⁺ and CD8⁺ T cells, we also found a unique population,

435 SARS-CoV-2-specific CD3⁺CD4⁺CD8⁻ T cells persisted 5 months after the
436 second immunization with inactivated vaccines, which were further elevated by
437 the third vaccination (Fig. 3F and G).

438

439 **A third dose of inactivated SARS-CoV-2 vaccine boosts immune**
440 **responses in individuals with negative serologic responses to 2 doses.**

441 The weakened or negative serological response has been noted in a small
442 group of vaccinees who had no known immunodeficiency disease or were not
443 in an immune-compromised condition. It is unclear that whether these people
444 are true “non-responders”, and whether a third dose is necessary and
445 beneficial as in immune-compromised patients^{33, 34}. In this study, we found
446 NAbS were below the threshold in 9 participants after the primary 2-dose
447 regimen. Of note, these participants have no known immunodeficiency disease
448 or are not in an immune-compromised condition. The level of NAbS in all of the
449 9 participants increased rapidly within 1 week and reach the peak 2 weeks
450 after the booster shot (Fig. 5A), though NAbS levels in these 9 participants
451 were still significantly lower than others who were seropositive after the second
452 dose (Fig. 5B).

453

454 The rapid recall of humoral responses indicated that the immune memory had
455 been successfully established in these seronegative people after the second
456 dose and persisted for at least 5 months. As expected, SARS-CoV-2-specific

457 memory B cells were indeed detected by labeling antigen-binding BCR in
458 these individuals on d56 and d180. The percentage of SARS-CoV-2-specific
459 memory B cells was quite stable over time between d56 and d180, and
460 increased significantly after the third dose (Fig. 5C). ELISpot was next enrolled
461 to identify functional memory B and T cells. Although no NABs were detected
462 at any time point before the third dose, spike- or RBD-specific IgG-secreting
463 memory B cells were able to be detected by ELISpot on d56 and maintained at
464 a similar level till d180. The number increased within 1 week after the third
465 dose and persisted thereafter (Fig. 5D and F).

466

467 Spike-specific T cells were also able to be detected on d56 and d180 as
468 measured by ELISpot, albeit with a downward trend (Fig. 5G and H). As
469 expected, the third dose was capable of enhancing T cell responses in this
470 population (Fig. 5H). The enhancement on SARS-CoV-2-specific CD4⁺ and
471 CD8⁺ T cells by the third dose was further confirmed by measuring AIM⁺ T cells
472 (OX40⁺4-1BB⁺ for CD4⁺ T cells and CD69⁺4-1BB⁺ for CD8⁺ T cells) by flow
473 cytometry. Both spike-specific CD4⁺ T cells and CD8⁺ T cells were successfully
474 expanded (Fig. 5I and J). We also observed the expansion of
475 SARS-CoV-2-specific cTFH cells in these participants (Fig. 5K). Taken
476 together, these results suggested that these participants were not true “no
477 responders”, immune memory had been established but repeated antigen
478 stimulations were needed.

479

480 **Discussion**

481 In this study, we investigated the duration of B cell and T cell immunity
482 following the primary 2-dose vaccination regimen of the inactivated
483 SARS-CoV-2 vaccine BBIBP-CorV and the potential benefit of a third dose in a
484 non-randomized trial. Data in this study showed that neutralizing antibodies
485 gradually decreased after the second dose during a 5-month observation.
486 SARS-CoV-2-specific B cells and T cells were detected and persisted in the
487 peripheral blood 5 months after the second vaccination. Both humoral and
488 cellular responses were rapidly and robustly elevated by a third dose of
489 inactivated SARS-CoV-2 vaccine. The induction of both SARS-CoV-2-specific
490 memory B cells and T cells by the inactivated vaccine supports durable
491 protection, as has been shown in mRNA vaccines and other settings^{35, 36}.
492 Another key observation in this study was the successful induction of
493 antigen-specific memory B cell and T cell response in HCWs with low
494 serological response to 2 doses of inactivation vaccines.

495

496 The NAb titers have been noted to decay following vaccination or SARS-CoV-2
497 infection³⁷⁻³⁹. However, HCWs who have recovered from COVID-19 show a
498 substantially lower risk of reinfection with SARS-CoV-2⁴⁰. The number of
499 RBD-specific memory B cells remained relatively stable between 6 and 12
500 months after SARS-CoV-2 infection and BCR repertoire expanded markedly in

501 these recovered patients after receiving an mRNA vaccine⁴¹. Consistently, we
502 found that spike- and RBD-specific memory B cells could still be detected in all
503 COVID-19 convalescent patients up to 13 months after infection
504 (Supplementary Fig. 6). SARS-CoV-2 mRNA vaccines were also capable of
505 inducing sustained immune memory and long-term protecting effects^{35, 42, 43}.
506 Our study, together with these aforementioned studies, suggests that
507 SARS-CoV-2-specific memory B cells may sustain longer than plasma cells.
508 Prediction of vaccine efficacy should not solely rely on NAbs titers. Rather,
509 memory B cells should be taken into account whenever it is possible.

510

511 Recently, a third dose of inactivated vaccine CoronaVac elicited a rapid and
512 long-lasting recall antibody response with the capability of neutralizing several
513 VOCs⁴⁴. The rapid and strong secondary response by the inactivated vaccine
514 represents a characteristic secondary immune response, which demonstrates
515 the establishment of long-term immune memory within these participants. Our
516 data confirm that SARS-CoV-2-specific memory B cells persisted 6 months
517 later the primary vaccination and expanded substantially by a third dose of
518 vaccine. The secondary immune response is one of the most important
519 features of immune memory stimulated by vaccination, which is characterized
520 by a faster and stronger immune response by memory B cells or plasma cells⁴⁵.
521 Despite the waning of antibodies, the generation of SARS-CoV-2-specific
522 memory B cells could mediate recall response in future infection and provide

523 protective immunity. As has been observed in recovered COVID-19 patients,
524 long-lived bone marrow spike-binding plasma cells are quiescent²⁷, which
525 explains the declining antibodies over time. Nonetheless, further investigation
526 should be conducted on how waning immunity could affect protection against
527 COVID-19.

528

529 Our data revealed that long-lasting memory B cells formed a basis for an
530 enormous lift of serum NAbs after the third dose, not only against WT
531 SARS-CoV-2 but also against B.1.617.2 Delta variant. As shown in
532 Supplementary Fig.1, the inactivated vaccine induced a broad spectrum of
533 antibody responses to multiple structural proteins of the virus. Whether the
534 lifted cross-reactive NAbs still targeted to RBD, or other domains of S protein,
535 or even other proteins were involved, is an interesting question meriting further
536 study.

537

538 Our study showed that SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in
539 convalescent COVID-19 patients could persist up to 13 months
540 (Supplementary Fig. 7). SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells induced
541 by BBIBP-CorV were detected in all the HCWs who received 2 doses of
542 vaccine and last for at least 5 months. In line with previous data from an mRNA
543 vaccine²⁰, SARS-CoV-2-specific CD4⁺ T cells induced by inactivated vaccine
544 mainly fall into central and effector memory subsets, while the majority of

545 SARS-CoV-2-specific CD8⁺ T cells were T_{EMRA} cells. Because of the high
546 CCR7 expression, the central memory T cells reside in the secondary
547 lymphoid organs and readily expand upon infection or booster vaccination.
548 Effector memory T cells circulate in between blood and peripheral tissues,
549 providing prompt immune response at the early time point of infection^{46, 47}. For
550 the emergence of VOCs of SARS-CoV-2, there is growing concern over
551 vaccine efficacy. In addition, T cells from COVID-19 convalescents and in
552 recipients of mRNA vaccine could recognize epitopes throughout the
553 SARS-CoV-2 spike protein and the total reactivity against SARS-CoV-2
554 variants of B.1.1.7, B.1.351, P.1, and CAL.20C lineages were mostly
555 maintained in terms of magnitude and frequency of response⁴⁸.
556 SARS-CoV-2-specific T cells from convalescent COVID-19 patients or
557 vaccinated individuals targeted the conserved epitopes between prototype and
558 VOCs^{49, 50}. Thus, SARS-CoV-2-specific T cells are less likely to be affected by
559 antibody escapes mutations in VOCs. Moreover, the inactivated virus vaccine
560 comprises all viral structural proteins. This means more epitopes, especially
561 those conserved epitopes in proteins other than spike are engaged as
562 compared to mRNA or recombinant protein vaccines involving only RBD or
563 spike. Ideally, a potent adjuvant rather than aluminum salts should be used to
564 fully realize this advantage.

565

566 Another interesting finding of this study was the induction of

567 SARS-CoV-2-specific cTFH cells by the inactivated vaccine. Our previous
568 study has demonstrated the mobilization of cTFH cells after the first dose of
569 inactivated vaccination¹¹. For the relatively late development of humoral
570 response by the inactivated vaccines, early response of cTFH cells could
571 contribute to the early protection of vaccination when antibody level was still
572 low^{3, 51}. cTFH cells have been associated with humoral response in COVID-19
573 patients or vaccination individuals^{20, 23}. Data in this study further confirmed that
574 the induction of cTFH cells by the inactivated vaccine correlated with humoral
575 response closely.

576

577 A third dose of the SARS-CoV-2 vaccine may be particularly in need for the
578 immunocompromised population. Low seroconversion rates to mRNA
579 vaccination have been reported in solid transplant recipients⁵². The
580 applications of immune suppressants or B cell-targeted therapies could also
581 hamper serological response to vaccination^{53, 54}. Recently, data show that
582 antibody response was enhanced in kidney transplant recipients with minimal
583 serologic response to 2 doses by a third dose of mRNA vaccine³³. In this study,
584 we found that a group of healthy individuals was not mounted with detectable
585 NAbs by two doses of vaccination. However, memory B and T cells could be
586 detected 5 months after the second immunization. The third dose of
587 inactivated vaccine could induce an elevated level of NAbs and an extensive
588 expansion of memory cells within 1 week, suggesting that the memory

589 response could also be effectively recalled upon SARS CoV-2 infection.

590 Therefore, these individuals were not true “non-responders” but already

591 equipped with immune memory which may at least confer protection against

592 severe diseases. Nevertheless, it should be noted that further studies are

593 needed to confirm the relevance between these memory responses and

594 protection. Moreover, a third dose is necessary to further secure the protection.

595

596 In conclusion, our study revealed sustained memory B and T cell responses

597 after a standard 2-dose vaccination regimen of inactivated vaccines. Immune

598 responses against SARS-CoV-2 were readily recalled and further elevated by

599 a third dose of the inactivated vaccine, which is especially beneficial for

600 individuals facing high exposure risks, such as HCWs, and has been

601 demonstrated to be safe and effective in our study and others^{33, 55}.

602

603 **Author Contributions:**

604 HX, HZ and JW supervised the study. YL, QZeng, CD, MLi, LL and DL

605 contributed equally to the study. HX, HZ, JW and YL conceived and designed

606 the study. YL, DL, JM and RM recruited participants in the trial and collected

607 blood samples. QZeng, CD, ML, MLi and LL performed the experiments and

608 collected data. QZeng and QZhou performed statistical analysis. HZ, YL,

609 QZeng, CD, MLi, LL and DL drafted the report. HX, JW, SP and MLiu made

610 critical revision on the manuscript. All authors contributed to the interpretation

611 of data. All authors approved the final version before submission.

612

613 **Acknowledgment**

614 We thank Prof. Lu Lu at Fudan University for his kind help in pseudovirus

615 assays. The work is supported by The Talent Program of the First Affiliated

616 Hospital, Sun Yat-sen University (Y70311) and The Hundred Talent Program of

617 Sun Yat-sen University (Y61229).

618

619 **Conflict interests:** The authors have no conflicts of interest to disclose.

620

621

622 **Reference:**

623 1 Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms,
624 risk factors, and management. *BMJ* 2021; **374**:n1648.

625 2 COVID-19 Map - Johns Hopkins Coronavirus Resource Center.
626 <https://coronavirus.jhu.edu/maphtml> 2021.

627 3 Xia S, Zhang Y, Wang Y *et al.* Safety and immunogenicity of an inactivated
628 SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind,
629 placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* 2021; **21**:39-51.

630 4 Jackson LA, Anderson EJ, Roupael NG *et al.* An mRNA Vaccine against
631 SARS-CoV-2 - Preliminary Report. *N Engl J Med* 2020; **383**:1920-1931.

632 5 Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines -
633 Safety and Efficacy Follow-up Considerations. *N Engl J Med* 2020; **383**:e107.

634 6 Khoury DS, Cromer D, Reynaldi A *et al.* Neutralizing antibody levels are
635 highly predictive of immune protection from symptomatic SARS-CoV-2
636 infection. *Nat Med* 2021; **27**:1205-1211.

637 7 Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently
638 needed. *Nat Med* 2021; **27**:1147-1148.

639 8 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure,
640 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020;
641 **181**:281-292 e286.

642 9 Goel RR, Apostolidis SA, Painter MM *et al.* Distinct antibody and memory B
643 cell responses in SARS-CoV-2 naive and recovered individuals following

- 644 mRNA vaccination. *Sci Immunol* 2021; **6**.
- 645 10 Xia S, Duan K, Zhang Y *et al*. Effect of an Inactivated Vaccine Against
646 SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2
647 Randomized Clinical Trials. *JAMA* 2020; **324**:951-960.
- 648 11 Zhang H, Liu Y, Liu D *et al*. Time of day influences immune response to an
649 inactivated vaccine against SARS-CoV-2. *Cell Res* 2021.
- 650 12 Marot S, Malet I, Leducq V *et al*. Rapid decline of neutralizing antibodies
651 against SARS-CoV-2 among infected healthcare workers. *Nat Commun* 2021;
652 **12**:844.
- 653 13 Shrotri M, Navaratnam AMD, Nguyen V *et al*. Spike-antibody waning after
654 second dose of BNT162b2 or ChAdOx1. *Lancet* 2021; **398**:385-387.
- 655 14 Krause PR, Fleming TR, Longini IM *et al*. SARS-CoV-2 Variants and
656 Vaccines. *N Engl J Med* 2021; **385**:179-186.
- 657 15 Pegu A, O'Connell S, Schmidt SD *et al*. Durability of mRNA-1273
658 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 2021.
- 659 16 Soresina A, Moratto D, Chiarini M *et al*. Two X-linked agammaglobulinemia
660 patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr*
661 *Allergy Immunol* 2020; **31**:565-569.
- 662 17 Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery
663 from COVID-19 in a B-cell-depleted multiple sclerosis patient. *Mult Scler* 2020;
664 **26**:1261-1264.
- 665 18 Oberhardt V, Luxenburger H, Kemming J *et al*. Rapid and stable

- 666 mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. *Nature* 2021.
- 667 19 Kared H, Redd AD, Bloch EM *et al.* SARS-CoV-2-specific CD8+ T cell
668 responses in convalescent COVID-19 individuals. *J Clin Invest* 2021; **131**.
- 669 20 Painter MM, Mathew D, Goel RR *et al.* Rapid induction of antigen-specific
670 CD4(+) T cells is associated with coordinated humoral and cellular immunity to
671 SARS-CoV-2 mRNA vaccination. *Immunity* 2021.
- 672 21 Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* 2011;
673 **29**:621-663.
- 674 22 Boppana S, Qin K, Files JK *et al.* SARS-CoV-2-specific circulating T
675 follicular helper cells correlate with neutralizing antibodies and increase during
676 early convalescence. *PLoS Pathog* 2021; **17**:e1009761.
- 677 23 Juno JA, Tan HX, Lee WS *et al.* Humoral and circulating follicular helper T
678 cell responses in recovered patients with COVID-19. *Nat Med* 2020;
679 **26**:1428-1434.
- 680 24 Deng Y, Li Y, Yang R, Tan W. SARS-CoV-2-specific T cell immunity to
681 structural proteins in inactivated COVID-19 vaccine recipients. *Cell Mol*
682 *Immunol* 2021; **18**:2040-2041.
- 683 25 Tenbusch M, Schumacher S, Vogel E *et al.* Heterologous prime-boost
684 vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis* 2021;
685 **21**:1212-1213.
- 686 26 Dan JM, Mateus J, Kato Y *et al.* Immunological memory to SARS-CoV-2
687 assessed for up to 8 months after infection. *Science* 2021; **371**.


- 688 27 Turner JS, Kim W, Kalaidina E *et al.* SARS-CoV-2 infection induces
689 long-lived bone marrow plasma cells in humans. *Nature* 2021; **595**:421-425.
- 690 28 Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N.
691 Optimization of a human IgG B-cell ELISpot assay for the analysis of
692 vaccine-induced B-cell responses. *J Immunol Methods* 2013; **391**:50-59.
- 693 29 Long QX, Jia YJ, Wang X *et al.* Immune memory in convalescent patients
694 with asymptomatic or mild COVID-19. *Cell Discov* 2021; **7**:18.
- 695 30 Peng Y, Mentzer AJ, Liu G *et al.* Broad and strong memory CD4(+) and
696 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals
697 following COVID-19. *Nat Immunol* 2020; **21**:1336-1345.
- 698 31 Xia S, Liu M, Wang C *et al.* Inhibition of SARS-CoV-2 (previously
699 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor
700 targeting its spike protein that harbors a high capacity to mediate membrane
701 fusion. *Cell Res* 2020; **30**:343-355.
- 702 32 Tea F, Ospina Stella A, Aggarwal A *et al.* SARS-CoV-2 neutralizing
703 antibodies: Longevity, breadth, and evasion by emerging viral variants. *PLoS*
704 *Med* 2021; **18**:e1003656.
- 705 33 Benotmane I, Gautier G, Perrin P *et al.* Antibody Response After a Third
706 Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant
707 Recipients With Minimal Serologic Response to 2 Doses. *JAMA* 2021.
- 708 34 Hall VG, Ferreira VH, Ku T *et al.* Randomized Trial of a Third Dose of
709 mRNA-1273 Vaccine in Transplant Recipients. *N Engl J Med* 2021.

- 710 35 Goel RR, Painter MM, Apostolidis SA *et al.* mRNA Vaccination Induces
711 Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants
712 of Concern. *bioRxiv* 2021.
- 713 36 Akondy RS, Fitch M, Edupuganti S *et al.* Origin and differentiation of human
714 memory CD8 T cells after vaccination. *Nature* 2017; **552**:362-367.
- 715 37 Israel A, Shenhar Y, Green I *et al.* Large-scale study of antibody titer decay
716 following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. *medRxiv* 2021.
- 717 38 Long QX, Tang XJ, Shi QL *et al.* Clinical and immunological assessment of
718 asymptomatic SARS-CoV-2 infections. *Nat Med* 2020; **26**:1200-1204.
- 719 39 Ibarondo FJ, Fulcher JA, Goodman-Meza D *et al.* Rapid Decay of
720 Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med*
721 2020; **383**:1085-1087.
- 722 40 Hall VJ, Foulkes S, Charlett A *et al.* SARS-CoV-2 infection rates of
723 antibody-positive compared with antibody-negative health-care workers in
724 England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 2021;
725 **397**:1459-1469.
- 726 41 Wang Z, Muecksch F, Schaefer-Babajew D *et al.* Naturally enhanced
727 neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*
728 2021; **595**:426-431.
- 729 42 Doria-Rose N, Suthar MS, Makowski M *et al.* Antibody Persistence through
730 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl*
731 *J Med* 2021; **384**:2259-2261.

- 732 43 Tenforde MW, Self WH, Naioti EA *et al.* Sustained Effectiveness of
733 Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated
734 Hospitalizations Among Adults - United States, March-July 2021. *MMWR Morb*
735 *Mortal Wkly Rep* 2021; **70**:1156-1162.
- 736 44 Kang W. ea. A third dose of inactivated vaccine 1 augments the potency,
737 breadth, and duration of anamnestic responses against SARS-CoV-2.
738 *medRxiv* 2021.
- 739 45 Quast I, Tarlinton D. B cell memory: understanding COVID-19. *Immunity*
740 2021; **54**:205-210.
- 741 46 Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation:
742 implications for vaccine development. *Nat Rev Immunol* 2002; **2**:251-262.
- 743 47 Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector
744 memory T cell subsets: function, generation, and maintenance. *Annu Rev*
745 *Immunol* 2004; **22**:745-763.
- 746 48 Tarke A, Sidney J, Methot N *et al.* Impact of SARS-CoV-2 variants on the
747 total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals.
748 *Cell Rep Med* 2021; **2**:100355.
- 749 49 Skelly DT, Harding AC, Gilbert-Jaramillo J *et al.* Two doses of SARS-CoV-2
750 vaccination induce robust immune responses to emerging SARS-CoV-2
751 variants of concern. *Nat Commun* 2021; **12**:5061.
- 752 50 Redd AD, Nardin A, Kared H *et al.* CD8+ T-Cell Responses in COVID-19
753 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent

- 754 SARS-CoV-2 Circulating Variants. *Open Forum Infect Dis* 2021; **8**:ofab143.
- 755 51 Al Kaabi N, Zhang Y, Xia S *et al.* Effect of 2 Inactivated SARS-CoV-2
756 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized
757 Clinical Trial. *JAMA* 2021; **326**:35-45.
- 758 52 Boyarsky BJ, Werbel WA, Avery RK *et al.* Antibody Response to 2-Dose
759 SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
760 *JAMA* 2021; **325**:2204-2206.
- 761 53 Haberman RH, Herati R, Simon D *et al.* Methotrexate hampers
762 immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated
763 inflammatory disease. *Ann Rheum Dis* 2021.
- 764 54 Mrak D, Tobudic S, Koblischke M *et al.* SARS-CoV-2 vaccination in
765 rituximab-treated patients: B cells promote humoral immune responses in the
766 presence of T-cell-mediated immunity. *Ann Rheum Dis* 2021.
- 767 55 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three
768 Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *N*
769 *Engl J Med* 2021; **385**:661-662.
- 770
- 771

772 **Figures and legends**



773

774 **Figure 1 Humoral responses induced by a third dose of inactivated**

775 **SARS-CoV-2 vaccine BBIBP-CorV. (A) Protocol of the prospective cohort**

776 **and the non-randomized trial. Healthcare workers (HCWs) were recruited from**


777 **a perspective cohort who received two doses of an inactivated vaccine either**

778 **in the morning (AM, n=25) or afternoon (PM, n=25) on day (d) 0 and d28. They**

779 **were assigned to morning or afternoon vaccination to receive a third dose of**

780 **the inactivated vaccine on day 180 according to their previous vaccinating time.**

781 Blood samples were collected on different time points d0 (T1), d14 (T2), d21
782 (T3), d28 (T4), d56 (T5), d180 (T6), d187 (T7), d194 (T8) and d208 (T9). (B-E)
783 Neutralizing antibodies (NAbs) against SARS-CoV-2 in the serum of each
784 volunteer was measured by Chemifluorescence Assay longitudinally. (B) The
785 concentration of NAbs in the sera at different time points was summarized and
786 shown in the box plot. (C) The longitudinal changes of NAbs in the sera before
787 and after the third dose of vaccination. (D) NAbs in the sera from the morning
788 or afternoon group at different time points. (E) NAbs concentrations in the sera
789 of female or male. Medians of the data were shown. (F, G) Neutralizing
790 activities of sera from T6 and T8 against SARS-CoV-2 wild type (WT) and
791 Delta variant (B.1.167.2) were measured by pseudovirus neutralizing assay. (H,
792 I) Comparison of neutralizing activities between the morning and afternoon
793 group on T8. Data are mean \pm SEM. Comparisons were done by Wilcoxon
794 rank sum test in B, D, E or Student's t-test in F-I. ** $p < 0.01$, **** $p < 0.0001$; ns,
795 not significant.
796
797



798

799 **Figure 2 SARS-CoV-2-specific memory B cell after a third dose of**


800 **inactivated vaccine.** Recombinant spike or receptor binding domain (RBD)

801 proteins were used to label SARS-CoV-2-specific BCRs. Data were acquired

802 by flow cytometry. (A, C) Representative FACS plots for spike- or RBD-specific

803 BCR were shown. (B, D) Longitudinal changes of spike- or RBD-specific

804 memory B cells were summarized. (E) IgG⁺, IgA⁺ and IgM⁺ B cells were
805 measured by flow cytometry. UMAP plot demonstrated the distribution of
806 spike- and RBD-specific memory B cells in IgG⁺, IgA⁺ and IgM⁺ B cells. (F)
807 Mean percentages of each BCR subtype in spike- and RBD-specific B cells
808 were summarized. (G) Spike- or RBD-specific IgG-secreting B cells were
809 measured by ELISpot after incubating PBMCs in spike- or RBD-coated plates
810 for 18 h. Representative ELISpot images were shown. (H, I) Numbers of Spike-
811 or RBD-specific IgG-secreting B cells per 10⁶ PBMCs were summarized.
812 Comparisons were done by one-way ANOVA corrected for multiple
813 comparison in panels B, D and Student's paired-T test in panels H and I.
814 ***p<0.001, ****p<0.0001; ns, not significant.
815



816

817 **Figure 3 Cellular responses induced by a third dose of inactivated**

818 **SARS-CoV-2 vaccine.** (A) PBMCs were stimulated with or without the spike

819 peptide pool (2 μ g/ml). Anti-CD3/CD28 dynabeads served as positive control.

820 IFN γ producing T cells were detected by ELISpot after 24 h incubation.

821 Representative images of ELISpot wells were shown. (B) The number of


822 IFN γ -producing T cells was quantified as the spot-forming units (s.f.u.) per 10^6

823 PBMCs. (C-G) PBMCs were stimulated with spike peptide pool (2 μ g/ml) for 12

824 h. Activation-induced markers (AIM) CD69 and 4-1BB were measured by flow

825 cytometry. (C) Representative FACS plots showing the SARS-CoV-2-specific

826 AIM⁺ CD8⁺ T cells. (D) Percentages of AIM⁺ CD8⁺ T cells were summarized. (E)
827 T_N (CD45RA⁺CCR7⁺), T_{EM} (CD45RA⁻CCR7⁻), T_{CM} (CD45RA⁻CCR7⁺), T_{ERMA}
828 (CD45RA⁺CCR7⁻) populations in AIM⁺ CD8⁺ T cells. (F, G)
829 SARS-CoV-2-specific CD3⁺CD4⁻CD8⁻ (DN) T cells were identified by CD69
830 and 4-1BB after spike peptide pool stimulation. (H, I) Intracellular cytokine
831 staining assays were performed to confirm the presence of
832 SARS-CoV-2-specific CD8⁺ T cells in PBMCs by measuring intracellular IFN γ
833 expression after peptide pool stimulation. Comparisons were done by
834 Student's paired-T test in panels B, D and G and one-way ANOVA corrected
835 for multiple comparison in panel I. ****p<0.0001; ns, not significant.
836



837

838 **Figure 4 Rapid induction of CD4⁺ T cells by the third dose.** (A, B)

839 Activation-induced markers (AIM) OX40 and 4-1BB in CD4⁺ T cells were
840 detected after incubating PBMCs with spike peptide pool (2 μg/ml) for 12 h.

841 Percentages of AIM⁺ CD4⁺ T cells in the PBMCs were summarized. (C) T_N


842 (CD45RA⁺CCR7⁺), T_{EM} (CD45RA⁻CCR7⁻), T_{CM} (CD45RA⁻CCR7⁺), T_{ERMA}

843 (CD45RA⁺CCR7⁻) populations in AIM⁺ CD4⁺ T cells were gated. (D)

844 Expression of CXCR5 in AIM⁺ CD4⁺ T cells was measured by flow cytometry.

845 (E) Percentages of circulating follicular helper T cells (cTFH) in total CD4⁺ T

846 cells were summarized. (F) UMAP plot showed the distribution of cTFH cells
847 among AIM⁺ CD4⁺ T cells. (G) Percentage of cTFH cells in AIM⁺ CD4⁺ T cells.
848 (H, I) Intracellular cytokine staining assays were performed to confirm the
849 presence of SARS-CoV-2-specific CD4⁺ T cells in PBMCs by measuring
850 intracellular IFN γ expression after peptide pool stimulation. Comparisons were
851 done by Student's paired-T test in panels B and E and one-way ANOVA
852 corrected for multiple comparison in panel I. *p<0.05, ***p<0.001,
853 ****p<0.0001.
854



855

856 **Figure 5 Immune responses in healthcare workers with minimal**

857 **serologic response to a standard two-dose vaccination schedule. (A)**

858 **Serum NAbs in HCWs with minimal serologic response to a standard two-dose**

859 **vaccination schedule were analyzed longitudinally at different time points**

860 **before and after the third dose (red arrow). (B) Comparison of NAbs between**

861 vaccinees with negative or positive serological responses to a standard
862 two-dose vaccination schedule. (C) Percentages of spike-specific memory B
863 cells in HCWs with a negative serological response to a standard two-dose
864 vaccination schedule. (D-F) Numbers of spike- or RBD-specific IgG-producing
865 B cells in HCWs with a negative serological response to a standard two-dose
866 vaccination schedule. (G, H) Numbers of spike-specific IFN γ producing T cells
867 as detected by ELISpot in HCWs with a negative serological response to a
868 standard two-dose vaccination schedule. (I-K) Spike-specific T cells, including
869 CD69⁺4-1BB⁺CD8⁺ T cells, OX40⁺4-1BB⁺CD4⁺ T cells and
870 CXCR5⁺OX40⁺4-1BB⁺ cTFH in HCWs with a negative serological response to
871 a standard two-dose vaccination schedule. Comparisons were done by
872 Wilcoxon rank sum test in B and One-way ANOVA corrected for multiple
873 comparison in the rest panels. *p<0.05, **p<0.01, ****p<0.0001; ns, not
874 significant.

875